Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding

Thrombosis and Haemostasis
Richard J FriedmanJoseph Caprini

Abstract

Patients undergoing total hip or knee arthroplasty should receive anticoagulant therapy because of the high risk of venous thromboembolism. However, many are already taking non-steroidal anti-inflammatory drugs (NSAIDs) or acetylsalicylic acid (ASA) that can have antihaemostatic effects. We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA. A post-hoc analysis was undertaken of the pooled data from trials comparing dabigatran etexilate (220 mg and 150 mg once daily) and enoxaparin. Major bleeding event (MBE) rates were determined and odds ratios (ORs) generated for patients who received study treatment plus NSAID (half-life ≤12 hours) or ASA (≤160 mg/day) versus study treatment alone. Relative risks were calculated for comparisons between treatments. Overall, 4,405/8,135 patients (54.1%) received concomitant NSAID and 386/8,135 (4.7%) received ASA.ORs for the comparison with/without concomitant NSAID were 1.05 (95% confidence interval [CI] 0.55-2.01) for 220 mg dabigatran etexilate; 1.19 (0.55-2.55) for 150 mg; and 1.32 (0.67-2.57) for enoxaparin. ORs for the comparison with/without ASA were 1.14 (0.26-5.03); 1.64 (0.36-7.49); and 2.57 (0.83-7...Continue Reading

Associated Clinical Trials

References

Jul 1, 1993·The Journal of Bone and Joint Surgery. British Volume·M A McNally, R A Mollan
Nov 22, 2002·European Journal of Anaesthesiology·R SlappendelM L T Bugter
Jan 9, 2004·The Journal of Bone and Joint Surgery. American Volume·Enrico PolaErnesto De Santis
Jul 2, 2005·The Journal of Arthroplasty·Paul A Lotke, Jess H Lonner
Jun 15, 2007·Pathophysiology of Haemostasis and Thrombosis·Ola E DahlMagnus Andersson
Jan 13, 2011·Thrombosis and Haemostasis·Alexander G G Turpie, Charles Esmon
Oct 1, 2011·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·K WalentaM Böhm

❮ Previous
Next ❯

Citations

Jan 24, 2013·Journal of Thrombosis and Thrombolysis·Gwen M Bernacki, Richard C Becker
Aug 21, 2013·Best Practice & Research. Clinical Haematology·Daniel J Quinlan, Bengt I Eriksson
Jun 14, 2013·Journal of Hospital Medicine : an Official Publication of the Society of Hospital Medicine·Sosena KebedeJodi B Segal
May 6, 2015·Pharmacotherapy·Ilya M DanelichBrent N Reed
Apr 26, 2015·European Journal of Clinical Pharmacology·Jenni IlomäkiMaarit Jaana Korhonen
Aug 19, 2016·Expert Opinion on Drug Metabolism & Toxicology·Christos VoukalisEduard Shantsila
Oct 13, 2016·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Henriette JohansenWaleed Ghanima
Dec 12, 2012·European Heart Journal·Deborah M Siegal, Mark A Crowther
Jul 19, 2014·World Journal of Orthopedics·Garrett B AikensMichael P Rivey
Mar 15, 2015·Arteriosclerosis, Thrombosis, and Vascular Biology·Cory Messerschmidt, Richard J Friedman
Jul 12, 2020·British Dental Journal·Alexander J CrightonAlyson J Brown
Mar 31, 2016·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Ben GreenPeter A Brennan
Aug 20, 2015·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·UNKNOWN Redaktsiia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.